Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Alcohol Craving
NCT01631630Phase 2
Key facts
- Status
- Terminated
- Start
- May 2012
- Primary completion
- Sep 2015
- Countries
- 1
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Modality
- Small Molecules
- Drugs
- pioglitazone
- Conditions
- alcohol dependence
01
Overview
Phase 2, randomised, double-blind trial in alcohol dependence comparing Pioglitazone with Placebo (2 arms). Primary endpoints: Alcohol Craving in Response to the Alcohol Cue Script, Alcohol Craving in Response to the Lipopolysaccharide Challenge at 6 hours and 1 more. Started May 2012; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Pioglitazone
Pioglitazone (titrated to 45mg/day)
Placebo
Placebo matching pioglitazone
03
Who it enrols
Adults aged 21-65 with alcohol dependence, drinking within the past month, without serious medical or psychiatric conditions.
04
Endpoints
Primary
Alcohol Craving in Response to the Alcohol Cue Script
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Alcohol Craving in Response to the Stress Script
Secondary
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Beyond the preview
Go deeper on NCT01631630.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631630.